Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Urinary Kallidinogenase Combined With Reteplase in Acute Ischemic Stroke
NCT07483281Not yet recruiting
- Sponsor
- China-Japan Union Hospital of Jilin University
- Start
- May 2026
- Primary completion
- Mar 2028
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of human urinary kallidinogenase + Shuxuening injection in ischemic stroke (2 arms), sponsored by China-Japan Union Hospital of Jilin University. Primary endpoint: Proportion of patients with modified Rankin Scale 0-1 at 90 days. Planned start May 2026; status: not yet recruiting.
02
Drugs
human urinary kallidinogenase + Shuxuening injection
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07483281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07483281.